TMA risk stratification. The figure displays Kaplan-Meier survival curves for subjects with TMA (n = 39) examining proteinuria ≥30 mg/dL and serum sC5b-9 concentrations at the time of TMA diagnosis in (A) subjects with proteinuria of ≥30 mg/dL vs no proteinuria, (B) subjects with elevated serum sC5b-9 concentration vs normal sC5b-9 concentration, and (C) subjects with no proteinuria and normal sC5b-9, proteinuria ≥30 mg/dL and normal sC5b-9, no proteinuria, and elevated sC5b-9 and both proteinuria ≥30 mg/dL and elevated sC5b-9 at the time of TMA diagnosis.